# Bio-Techne completes acquisition of Exosome Diagnostics for up to $575 million

Bio-Techne Corporation completed its acquisition of Exosome Diagnostics, Inc. with an upfront payment of $250 million and up to $325 million in additional milestone payments through 2022.

- Type: Acquisition
- Announced: 2018-08-01
- Value: $575.0M
- Status: completed
- Products: liquid biopsy diagnostic tests, prostate molecular test (EPI)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Bio-Techne Corporation](https://endata.com/companies/33492.md) (acquirer)
- [Exosome Diagnostics](https://endata.com/companies/33493.md) (target)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/bio-techne-corporation-completed-its-acquisition-of-exosome-diagnostics-inc-300690481.html), 2018-08-01: "Bio-Techne Corporation today announced it has completed its acquisition of Exosome Diagnostics, Inc."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.